Drug Channels

JUNE 18, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Click here to see the original post from April 2024. Last week, we documented the substantial concentration of dispensing revenues for specialty drugs.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Documentation 52

Putting Patients First Blog

SEPTEMBER 3, 2024

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling Communication 52

Express Pharma

OCTOBER 2, 2024

Speaking at the recent ASSOCHAM Annual Pharma Summit 2024, Secretary, Department of Pharmaceuticals, Dr Arunish Chawla’s review of the regulatory reforms needs to go hand in hand with the growth opportunities.

Drug Pricing 105

Drug Pricing Documentation Labelling 105

Proxsys Rx

APRIL 19, 2024

And that is why the one 340B prediction we can make for 2024, unequivocally, is repeated three times in this post’s headline. Which means we may see a lot more states putting manufacturers in their place, in 2024. How covered entities should prepare for 340B changes in 2024 Build a qualified 340B team.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). This includes collecting data on utilization management practices, formulary changes, and patient experiences.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Big Molecule Watch

MARCH 1, 2024

Today, the district court for the District of Delaware (Judge Connolly) granted the government’s motion for summary judgment on all claims brought by AstraZeneca in its Complaint challenging the Drug Price Negotiation Program of the IRA. There are now seven remaining lawsuits challenging the Drug Price Negotiation Program of the IRA.

Biosimilars 59

Biosimilars Drug Pricing Dosage Documentation 59

Pharmaceutical Technology

JANUARY 6, 2023

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. Gilenya is an oral medication for multiple sclerosis. Fighting Entresto generics.

Documentation 97

Documentation Hospitals Dosage Drug Pricing 97

Ramblings of a pharmacist

FEBRUARY 16, 2022

It’s a well-thought through survey document, but I still have uncertainties about how to answer some of the questions – a part asks how many prescriptions were filled with brands and how many with generics. It’s an invaluable document, even if it isn’t perfect. How much were they?). 1) Most PBMs (not all!)

Independent Pharmacies 52

Independent Pharmacies Compounding Specialty Pharmacies Prescription Filling 52

Pharma in Brief

JANUARY 10, 2024

We also flag what to watch out for in 2024. Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Safe Biologics

MAY 10, 2024

From the post: The HHS Budget in Brief document describes the policy objective simply enough: “ Permit Biosimilar Substitution without Prior FDA Determination of Interchangeability” and clarifies that this means “deem all approved biosimilars to be interchangeable with their respective reference products”.

Biosimilars 130

Biosimilars Drug Pricing Documentation Labelling 130

Pharmaceutical Commerce

JUNE 18, 2025

9, 2024—seven weeks before the one-year stabilization period was set to end. 27 of this year to meet the requirements, as long as they are making documented efforts to finalize data connections, of course. The most recent enforcement delay came Oct. Next on the docket are wholesale distributors, who have until Aug.

Drug Pricing 52

Drug Pricing Specialty Pharmacies Pharmaceutical Manufacturing Documentation 52

Drug Channels

DECEMBER 11, 2024

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. You can also check out our recent data deep dive: Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis. Click here to see the original post.

Drug Pricing 52

Drug Pricing Documentation Hospitals 52

Proxsys Rx

JUNE 4, 2025

The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Two key 340B legal cases: There have been two very closely-watched federal court cases that address the ongoing dispute between drug manufacturers and the U.S.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Documentation Inventory Control 52

Express Pharma

FEBRUARY 10, 2025

What are the top 3 biopharma trends that you have observed in 2024 with India as a focused region as well as looking at it locally? Global trends: The emphasis on technology, AI, and generative AI is very strong within the biopharma sector, spanning areas like drug discovery, development, commercialisation, and the supply chain.

Documentation 100

Documentation Drug Pricing Biosimilars Labelling 100

BioPharma Dive

JUNE 5, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

Drug Pricing 52

Drug Pricing Drug Development Vaccines Pharmaceutical Manufacturing 52

PharmaVoice

JUNE 11, 2025

The 1,000-plus page document is full of tax and spending cuts, including some significant changes that will impact pharma and the larger healthcare industry. IRA reforms Industry advocates have pushed for reforms to the IRA since it passed during the Biden administration, with the focus squarely on the Medicare drug price negotiation program.

Drug Pricing 179

Drug Pricing Packaging Documentation 179

BioPharma Dive

JUNE 12, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Pharma’s wins and losses in the budget bill Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.

Drug Pricing 52

Drug Pricing Packaging Vaccines Documentation 52